Actelion Pharmaceuticals US, Inc. et al v. Cipla Limited et al
| Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. |
| Cipla Limited and Cipla USA Inc. |
| 1:2023cv00389 |
| April 6, 2023 |
| US District Court for the District of Delaware |
| Gregory B Williams |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 25, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
SO ORDERED, re (9 in 1:23-cv-00389-GBW, 17 in 1:22-cv-01450-GBW) STIPULATED ORDER Regarding Consolidation of Actions filed by Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. Signed by Judge Gregory B. Williams on 4/25/23. Associated Cases: 1:22-cv-01450-GBW, 1:23-cv-00389-GBW (ntl)
|
| Case associated with lead case: Create association to 1:22-cv-01450-GBW. ALL PAPERS SHALL BE FILED IN LEAD CASE NO. 22-1450-GBW ONLY. (ntl) |
| Filing 9 STIPULATION Regarding Consolidation of Actions, by Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc., Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd. (Balick, Steven) |
| Filing 8 WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd.: For Cipla USA Inc. waiver sent on 4/13/2023, answer due 6/12/2023. (Balick, Steven) |
| Filing 7 WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd.: For Cipla Limited waiver sent on 4/13/2023, answer due 6/12/2023. (Balick, Steven) |
| Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. Associated Cases: 1:23-cv-00383-GBW, 1:23-cv-00389-GBW (rjb) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nippon Shinyaku Co., Ltd. (jfm) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. filed by Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. (jfm) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,122; 9,284,280. (jfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 13, 2023. Date of Expiration of Patent: June 25, 2030 (U.S. Patent No. 9,284,280); August 1, 2030 (U.S. Patent No. 8,791,122).Thirty Month Stay Deadline: 9/13/2025. (jfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) |
| Filing 1 COMPLAINT filed against Cipla Limited, Cipla USA Inc. (Filing fee $ 402, receipt number ADEDC-4106721.) - filed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(jfm) |
| No Summons Issued. (jfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
